Nonalcoholic steatohepatitis (NASH) is a progressive disease that is often accompanied by
metabolic syndrome and poses a high risk of severe liver damage. However, no effective …

Activation of apoptosis signal-regulating kinase 1 (ASK1) in hepatocytes is a key process in
the progression of nonalcoholic steatohepatitis (NASH) and a promising target for treatment …

Liver cell death has an essential role in nonalcoholic steatohepatitis (NASH). The activity of
the energy sensor adenosine monophosphate (AMP)–activated protein kinase (AMPK) is …

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease and has become a
leading indication for liver transplantation in the United States. The development of effective …

Non‐alcoholic fatty liver disease (NAFLD) is strongly associated with obesity and may
progress to non‐alcoholic steatohepatitis (NASH) and liver fibrosis. The deficit of …

Activation of RIPK1-driven cell death and inflammation play important roles in the
progression of nonalcoholic steatohepatitis (NASH). However, the mechanism underlying …

Nonalcoholic steatohepatitis (NASH) is a common clinical condition that can lead to
advanced liver diseases. Lack of effective pharmacotherapies for NASH is largely …

Activation of apoptosis signal‐regulating kinase 1 (ASK1) is a key driving force of the
progression of nonalcoholic steatohepatitis (NASH) and represents an attractive therapeutic …

In human and murine models of nonalcoholic steatohepatitis (NASH), increased hepatocyte
apoptosis is a critical mechanism contributing to inflammation and fibrogenesis. Caspase 8 …

Non-alcoholic fatty liver disease (NAFLD) is an emerging liver disease worldwide. In subset
of patients, NAFLD progresses to its advanced form, nonalcoholic steatohepatitis (NASH) …